|
1
|
Lo KW, Chung GT and To KF: Deciphering the
molecular genetic basis of NPC through molecular, cytogenetic, and
epigenetic approaches. Semin Cancer Biol. 22:79–86. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maxwell JH, Kumar B, Feng FY, McHugh JB,
Cordell KG, Eisbruch A, Worden FP, Wolf GT, Prince ME, Moyer JS, et
al: HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma
in white North Americans. Head Neck. 32:562–567. 2010.PubMed/NCBI
|
|
4
|
Dawson CW, Port RJ and Young LS: The role
of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the
pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol.
22:144–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shah KM, Stewart SE, Wei W, Woodman CB,
O'Neil JD, Dawson CW and Young LS: The EBV-encoded latent membrane
proteins, LMP2A and LMP2B, limit the actions of interferon by
targeting interferon receptors for degradation. Oncogene.
28:3903–3914. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dawson CW, Rickinson AB and Young LS:
Epstein-barr virus latent membrane protein inhibits human
epithelial cell differentiation. Nature. 344:777–780. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Allen MD, Young LS and Dawson CW: The
Epstein-barr virus-encoded LMP2A and LMP2B proteins promote
epithelial cell spreading and motility. J Virol. 79:1789–1802.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oda K, Okada J, Timmerman L,
Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H,
Knight ZA, Shokat KM and McCormick F: PIK3CA cooperates with other
phosphatidylinositol 3′-kinase pathway mutations to effect
oncogenic transformation. Cancer Res. 68:8127–8136. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Corson TW and Crews CM: Molecular
understanding and modern application of traditional medicines:
Triumphs and trials. Cell. 130:769–774. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma J, Dey M, Yang H, Poulev A, Pouleva R,
Dorn R, Lipsky PE, Kennelly EJ and Raskin I: Anti-inflammatory and
immunosuppressive compounds from Tripterygium wilfordii.
Phytochemistry. 68:1172–1178. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang SX, Gao HL, Xie SS, Zhang WR and Long
ZZ: Immunosuppression of triptolide and its effect on skin
allograft survival. Int J Immunopharmacol. 14:963–969. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Banerjee S, Sangwan V, McGinn O, Chugh R,
Dudeja V, Vickers SM and Saluja AK: Triptolide-induced cell death
in pancreatic cancer is mediated by O-GlcNAc modification of
transcription factor Sp1. J Biol Chem. 288:33927–33938. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu PP, Liu KC, Huang WW, Ma CY, Lin H,
Yang JS and Chung JG: Triptolide induces apoptosis in human adrenal
cancer NCI-H295 cells through a mitochondrial-dependent pathway.
Oncol Rep. 25:551–557. 2011.PubMed/NCBI
|
|
14
|
Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei
XF, Yang J, Underhill CB and Zhang L: Triptolide inhibits the
growth and metastasis of solid tumors. Mol Cancer Ther. 2:65–72.
2003.PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiong J, Su T, Qu Z, Yang Q, Wang Y, Li J
and Zhou S: Triptolide has anticancer and chemosensitization
effects by down-regulating Akt activation through the MDM2/REST
pathway in human breast cancer. Oncotarget. 7:23933–23946. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Q, Lu Z, Jin Y, Wu Y and Pan J:
Triptolide inhibits Jak2 transcription and induces apoptosis in
human myeloproliferative disorder cells bearing Jak2V617F through
caspase-3-mediated cleavage of Mcl-1. Cancer Lett. 291:246–255.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carter BZ, Mak DH, Schober WD, Dietrich
MF, Pinilla C, Vassilev LT, Reed JC and Andreeff M: Triptolide
sensitizes AML cells to TRAIL-induced apoptosis via decrease of
XIAP and p53-mediated increase of DR5. Blood. 111:3742–3750. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu L, Li G, Li Q, Jin Z, Zhang L, Zhou J,
Hu X, Zhou T, Chen J and Gao N: Triptolide induces apoptosis in
human leukemia cells through caspase-3-mediated ROCK1 activation
and MLC phosphorylation. Cell Death Dis. 4:e9412013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang PY, Zeng WJ, Liu J, Wu YL, Ma Y, Zeng
Z, Pang JY, Zhang XK, Yan X, Wong AST and Zeng JZ: TRC4, an
improved triptolide derivative, specifically targets to truncated
form of retinoid X receptor-alpha in cancer cells. Biochemical
pharmacology. 124:19–28. 2017. View Article : Google Scholar : PubMed/NCBI
|
